Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Ph.D., Massachusetts Institute of Technology 2007
  • B.S., University of Kentucky, Lexington 2002
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2012 - 2020
  • Assistant Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2016 - 2019
• Recognition
• 

  In the News

  • SEP 16, 2019

    Pratt School of Engineering

    Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise

  • OCT 3, 2018

    Duke Med Alumni News

    From Innovation to Impact

  • APR 9, 2018

    Faculty Startup Sold to Belgian Pharma for $30 Million

  • OCT 25, 2017

    Duke Cancer Institute

    Why Do Perfectly Good Cancer Treatments Suddenly Stop Working?

  • NOV 19, 2015

    Duke Research Blog

    The Challenges of Combating Cancer Drug Resistance

  • JAN 5, 2015

    Researchers Map Paths to Cancer Drug Resistance
• Research
• 

  Selected Grants

  • Cell and Molecular Biology Training Program awarded by National Institutes of Health 2021 - 2026
  • Duke Center for Advancement of Child Health (CAtCH). awarded by National Institutes of Health 2021 - 2026
  • Genetic and Genomics Training Grant awarded by National Institutes of Health 2020 - 2025
  • Pharmacological Sciences Training Grant awarded by National Institutes of Health 2020 - 2025
  • NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma awarded by National Institutes of Health 2020 - 2025
  • Synthetic lethality by targeting the core senescent mechanism in lung cancer. awarded by National Institutes of Health 2020 - 2025
  • Institutional Summer Undergraduate Research Fellowship (SURF) awarded by American Society for Pharmacology and Experimental Therapeutics 2018 - 2025
  • ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets awarded by Department of Defense 2022 - 2024
  • Uncovering the functional dependencies of brain metastasis at genome-wide scale awarded by National Institutes of Health 2019 - 2024
  • Exploitation of XLF signaling and the DNA Damage Response as a novel therapeutic strategy in cholangiocarcinoma awarded by American College of Surgeons 2021 - 2023
  • Exploiting targeted therapy-induced ATM dependence in residual lung tumors awarded by Department of Defense 2021 - 2023
  • Defining the Mechanistic Determinants of Response to Selective Electron Transport Chain Inhibition in Cancer awarded by National Institutes of Health 2021 - 2023
  • Identification and Characterization of Novel Cis-Regulatory Elements Controlling PTEN Expression awarded by National Institutes of Health 2020 - 2022
  • Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer awarded by Department of Defense 2019 - 2022
  • Selectively targeting apoptosis in PIK3CA mutant colorectal cancers awarded by National Institutes of Health 2016 - 2022
  • Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
  • University Training Program in Biomolecular and Tissue Engineering awarded by National Institutes of Health 1994 - 2022
  • Computational Structure-Based Protein Design Non-competing Renewal (Yr. 12) awarded by National Institutes of Health 2008 - 2022
  • HOXB13 as a therapeutic target in prostate cancer awarded by Prostate Cancer Foundation 2020 - 2022
  • Determining the Sub-Cellular Organelles that Link Lipid Signaling and Epigenetics awarded by National Institutes of Health 2019 - 2021
  • Bioinformatics and Computational Biology Training Program awarded by National Institutes of Health 2005 - 2021
  • Mechanisms of immune checkpoint resistance mediated by LKB1 tumor suppressor in lung cancer awarded by Department of Defense 2019 - 2021
  • Strategies to overcome immunotherapy resistance in LKB1 and KEAP/NRF2 mutated NSCLC: modulating ferroptosis to restore immune sensitivity awarded by Society for Immunotherapy of Cancer 2020 - 2021
  • Decoding human genetic variation by functional dissection of beta2-adrenergic receptor signaling awarded by  American Heart Association 2019 - 2021
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance awarded by National Institutes of Health 2017 - 2021
  • Precision targeting of altered mitochondrial states in ovarian cancer awarded by Ovarian Cancer Research Fund, Inc. 2015 - 2021
  • Identification and validation of the PAX3-FOXO1 protein interactome awarded by St. Baldrick's Foundation 2018 - 2020
  • Targeting the Hippo pathway in Ras-driven rhabdomyosarcoma awarded by V Foundation for Cancer Research 2016 - 2020
  • High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity awarded by Celldom 2018 - 2020
  • Genetics Training Grant awarded by National Institutes of Health 1979 - 2020
  • Organization and Function of Cellular Structure awarded by National Institutes of Health 1975 - 2020
  • Pharmacological Sciences Training Program awarded by National Institutes of Health 1975 - 2020
  • Evaluating small molecules that potentiate anti-tumor immunity awarded by Tavros Therapeutics 2020
  • Topological Methods for Morphology: Classifying Shape and Function via Dictionary Learning awarded by Columbia University 2016 - 2020
  • Single cell functional dissection of tumor microenviornment-driven drug resistance awarded by National Institutes of Health 2018 - 2020
  • Pharmacology Industry Internships for Ph.D. Students awarded by American Society for Pharmacology and Experimental Therapeutics 2017 - 2019
  • Targeting differential apoptosis regulation in triple negative breast cancer awarded by Department of Defense 2016 - 2019
  • Identification of synthetic lethal interactors in pancreatic cancer awarded by University of North Carolina - Chapel Hill 2015 - 2019
  • Exploring BCL-XL addiction in pancreatic ductal adenocarcinoma awarded by National Institutes of Health 2016 - 2019
  • RalA signal transduction awarded by National Institutes of Health 2002 - 2019
  • Copy Number Alterations in Low Mutation Cancer awarded by National Institutes of Health 2018 - 2019
  • Exploiting collateral sensitivity to target kinase inhibitor-resistant lung cancers awarded by Burroughs Wellcome Fund 2017 - 2018
  • Unmasking targetable dependencies in cancer with intrinsic or acquired resistance to anti-cancer therapies awarded by National Institutes of Health 2017 - 2018
  • Integration of signaling and metabolic pathways in the regulation of EMT awarded by US-Israel Binational Science Foundation 2016 - 2018
  • Profiling Gene Interactions in the Human Kinome awarded by  National Science Foundation 2015 - 2018
  • Targeting undruggable oncogenes through the epigenome awarded by Element Genomics, Inc. 2017 - 2018
  • Designing durable apoptosis-targeting therapies for acute myeloid leukemia awarded by National Institutes of Health 2016 - 2018
  • Mapping the landscape of drug sensitizers in human cancers awarded by National Institutes of Health 2015 - 2017
  • Genomic and Computational Approaches for Development of Novel Anticancer Therapies awarded by Schlumberger Foundation 2015 - 2017
  • Systematic design of CDK4/6 inhibitor-based combination therapies awarded by G1 Therapeutics Inc. 2015 - 2016
  • A Platform for Real-time Drug Profiling of Patient-Derived Melanomas awarded by National Institutes of Health 2014 - 2016
  • Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
  • Systematic dissection of the breast cancer microenvironment using the MicroSCALE Toolkit awarded by V Foundation for Cancer Research 2013 - 2015
• 

  External Relationships

  • Celldom, Inc.
  • Element Genomics
  • Tavros Therapeutics
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Luttman, Jillian Hattaway, Jacob P. Hoj, Kevin H. Lin, Jiaxing Lin, Jing Jin Gu, Clay Rouse, Amanda G. Nichols, Nancie J. MacIver, Kris C. Wood, and Ann Marie Pendergast. “ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.” Cell Reports 37, no. 4 (October 2021): 109880. https://doi.org/10.1016/j.celrep.2021.109880.
       Full Text
    • Joh, Daniel Y., Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, et al. “Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.” Npj Breast Cancer 7, no. 1 (September 17, 2021): 126. https://doi.org/10.1038/s41523-021-00335-4.
       Full Text  Link to Item
    • Yellen, Benjamin B., Jon S. Zawistowski, Eric A. Czech, Caleb I. Sanford, Elliott D. SoRelle, Micah A. Luftig, Zachary G. Forbes, Kris C. Wood, and Jeff Hammerbacher. “Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.” Sci Adv 7, no. 38 (September 17, 2021): eabf9840. https://doi.org/10.1126/sciadv.abf9840.
       Full Text  Open Access Copy  Link to Item
    • Joh, Daniel Y., Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, et al. “Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.” Npj Breast Cancer 7, no. 1 (July 2, 2021): 85. https://doi.org/10.1038/s41523-021-00290-0.
       Full Text  Link to Item
    • Su, Angela, Frank Ling, Camille Vaganay, Gaetano Sodaro, Chaïma Benaksas, Reinaldo Dal Bello, Antoine Forget, et al. “The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.” Cancer Discov 10, no. 12 (December 2020): 1894–1911. https://doi.org/10.1158/2159-8290.CD-19-0970.
       Full Text  Link to Item
    • Ozkan-Dagliyan, Irem, J Nathaniel Diehl, Samuel D. George, Antje Schaefer, Bjoern Papke, Kathleen Klotz-Noack, Andrew M. Waters, et al. “Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.” Cell Rep 31, no. 11 (June 16, 2020): 107764. https://doi.org/10.1016/j.celrep.2020.107764.
       Full Text  Link to Item
    • Lin, Kevin H., Justine C. Rutter, Abigail Xie, Bryann Pardieu, Emily T. Winn, Reinaldo Dal Bello, Antoine Forget, et al. “Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.” Nat Genet 52, no. 4 (April 2020): 408–17. https://doi.org/10.1038/s41588-020-0590-9.
       Full Text  Link to Item
    • Wood, Kris C. “Overcoming MCL-1-driven adaptive resistance to targeted therapies.” Nature Communications 11, no. 1 (January 27, 2020): 531. https://doi.org/10.1038/s41467-020-14392-z.
       Full Text
    • Liberti, Maria V., Annamarie E. Allen, Vijyendra Ramesh, Ziwei Dai, Katherine R. Singleton, Zufeng Guo, Jun O. Liu, Kris C. Wood, and Jason W. Locasale. “Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis.” The Journal of Biological Chemistry 295, no. 1 (January 2020): 111–24. https://doi.org/10.1074/jbc.ra119.010903.
       Full Text
    • Zhong, Zheng, Sugunavathi Sepramaniam, Xin Hui Chew, Kris Wood, May Ann Lee, Babita Madan, and David M. Virshup. “PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.” Oncogene 38, no. 40 (October 2019): 6662–77. https://doi.org/10.1038/s41388-019-0908-1.
       Full Text  Link to Item
    • Manzari, Mandana T., Gray R. Anderson, Kevin H. Lin, Ryan S. Soderquist, Merve Çakir, Mitchell Zhang, Chandler E. Moore, et al. “Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.” Sci Adv 5, no. 9 (September 2019): eaaw9162. https://doi.org/10.1126/sciadv.aaw9162.
       Full Text  Link to Item
    • Cakir, Merve, Sayan Mukherjee, and Kris C. Wood. “Label propagation defines signaling networks associated with recurrently mutated cancer genes.” Sci Rep 9, no. 1 (June 28, 2019): 9401. https://doi.org/10.1038/s41598-019-45603-3.
       Full Text  Link to Item
    • Lin, Kevin H., Abigail Xie, Justine C. Rutter, Yeong-Ran Ahn, Julia M. Lloyd-Cowden, Amanda G. Nichols, Ryan S. Soderquist, et al. “Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.” Cell Metab 29, no. 5 (May 7, 2019): 1217-1231.e7. https://doi.org/10.1016/j.cmet.2019.01.011.
       Full Text  Link to Item
    • Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.
       Full Text  Link to Item
    • Ding, Yi, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin H. Lin, Gehao Liang, et al. “Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.” Nat Commun 9, no. 1 (October 15, 2018): 4274. https://doi.org/10.1038/s41467-018-06651-x.
       Full Text  Link to Item
    • Soderquist, Ryan S., Lorin Crawford, Esther Liu, Min Lu, Anika Agarwal, Gray R. Anderson, Kevin H. Lin, Peter S. Winter, Merve Cakir, and Kris C. Wood. “Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.” Nat Commun 9, no. 1 (August 29, 2018): 3513. https://doi.org/10.1038/s41467-018-05815-z.
       Full Text  Link to Item
    • Ohiri, Korine A., Sean T. Kelly, Jeffrey D. Motschman, Kevin H. Lin, Kris C. Wood, and Benjamin B. Yellen. “An acoustofluidic trap and transfer approach for organizing a high density single cell array.” Lab Chip 18, no. 14 (July 10, 2018): 2124–33. https://doi.org/10.1039/c8lc00196k.
       Full Text  Open Access Copy  Link to Item
    • Winter, Peter S., and Kris C. Wood. “Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.” Trends Cancer 4, no. 5 (May 2018): 333–35. https://doi.org/10.1016/j.trecan.2018.02.004.
       Full Text  Link to Item
    • Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Catherine Yip, Yeong-Ran Ahn, Moiez Ali, Alexander P. Yllanes, Christina A. Chao, Donald P. McDonnell, and Kris C. Wood. “Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.” Nat Commun 9, no. 1 (April 26, 2018): 1677. https://doi.org/10.1038/s41467-018-04033-x.
       Full Text  Link to Item
    • Crawford, Lorin, Kris C. Wood, Xiang Zhou, and Sayan Mukherjee. “Bayesian Approximate Kernel Regression with Variable Selection.” J Am Stat Assoc 113, no. 524 (2018): 1710–21. https://doi.org/10.1080/01621459.2017.1361830.
       Full Text  Link to Item
    • Singleton, Katherine R., Lorin Crawford, Elizabeth Tsui, Haley E. Manchester, Ophelia Maertens, Xiaojing Liu, Maria V. Liberti, et al. “Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.” Cell Rep 21, no. 10 (December 5, 2017): 2796–2812. https://doi.org/10.1016/j.celrep.2017.11.022.
       Full Text  Link to Item
    • Anderson, Grace R., Peter S. Winter, Kevin H. Lin, Daniel P. Nussbaum, Merve Cakir, Elizabeth M. Stein, Ryan S. Soderquist, et al. “A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.” Cell Rep 20, no. 4 (July 25, 2017): 999–1015. https://doi.org/10.1016/j.celrep.2017.07.006.
       Full Text  Link to Item
    • Ali, Moiez, Erin Kaltenbrun, Gray R. Anderson, Sarah Jo Stephens, Sabrina Arena, Alberto Bardelli, Christopher M. Counter, and Kris C. Wood. “Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.” Nat Commun 8 (June 8, 2017): 15617. https://doi.org/10.1038/ncomms15617.
       Full Text  Link to Item
    • Price, Alexander M., Joanne Dai, Quentin Bazot, Luv Patel, Pavel A. Nikitin, Reza Djavadian, Peter S. Winter, et al. “Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection.” Elife 6 (April 20, 2017). https://doi.org/10.7554/eLife.22509.
       Full Text  Open Access Copy  Link to Item
    • Wood, Kris C. “Suppressing oncogenic transcription with a little healthy competition.” Sci Transl Med 9, no. 374 (January 25, 2017). https://doi.org/10.1126/scitranslmed.aal5000.
       Full Text  Link to Item
    • Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, et al. “PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.” Sci Transl Med 8, no. 369 (December 14, 2016): 369ra175. https://doi.org/10.1126/scitranslmed.aae0348.
       Full Text  Open Access Copy  Link to Item
    • Wood, Kris C. “An EXITS strategy for decreasing cancer risk in women.” Sci Transl Med 8, no. 368 (December 7, 2016): 368ec197. https://doi.org/10.1126/scitranslmed.aal2806.
       Full Text  Link to Item
    • Wood, K. C. “Hacking T cells with synthetic circuits to program antitumor responses.” Science Translational Medicine 8, no. 362 (October 26, 2016). https://doi.org/10.1126/scitranslmed.aai9170.
       Full Text
    • Wood, K. C. “Two faces of circulating breast cancer cells.” Science Translational Medicine 8, no. 356 (September 14, 2016). https://doi.org/10.1126/scitranslmed.aah7023.
       Full Text
    • Wood, K. C. “Mapping a path for precision cancer therapies.” Science Translational Medicine 8, no. 348 (July 20, 2016). https://doi.org/10.1126/scitranslmed.aah4512.
       Full Text
    • Singleton, Katherine R., and Kris C. Wood. “Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes.” Genes Cancer 7, no. 7–8 (July 2016): 218–28. https://doi.org/10.18632/genesandcancer.112.
       Full Text  Open Access Copy  Link to Item
    • Wood, K. C. “Targeting the cancer cells that just won't go away.” Science Translational Medicine 8, no. 344 (June 22, 2016). https://doi.org/10.1126/scitranslmed.aag2112.
       Full Text
    • Lin, Kevin H., Peter S. Winter, Abigail Xie, Cullen Roth, Colin A. Martz, Elizabeth M. Stein, Grace R. Anderson, Jennifer P. Tingley, and Kris C. Wood. “Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.” Sci Rep 6 (June 10, 2016): 27696. https://doi.org/10.1038/srep27696.
       Full Text  Link to Item
    • Cribb, Jeremy A., Lukas D. Osborne, Kellie Beicker, Matthew Psioda, Jian Chen, E Timothy O’Brien, Russell M. Taylor Ii, et al. “An Automated High-throughput Array Microscope for Cancer Cell Mechanics.” Sci Rep 6 (June 6, 2016): 27371. https://doi.org/10.1038/srep27371.
       Full Text  Link to Item
    • Wood, K. C. “Collaborating tumor cells overcome multitargeted antiangiogenic therapies.” Science Translational Medicine 8, no. 338 (May 11, 2016). https://doi.org/10.1126/scitranslmed.aaf9190.
       Full Text
    • Park, Sunghee, Ching-Yi Chang, Rachid Safi, Xiaojing Liu, Robert Baldi, Jeff S. Jasper, Grace R. Anderson, et al. “ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.” Cell Rep 15, no. 2 (April 12, 2016): 323–35. https://doi.org/10.1016/j.celrep.2016.03.026.
       Full Text  Link to Item
    • Wood, K. C. “Intercepting reversible drug tolerance to improve targeted therapy.” Science Translational Medicine 8, no. 332 (March 30, 2016). https://doi.org/10.1126/scitranslmed.aaf6467.
       Full Text
    • Son, Sungmin, Mark M. Stevens, Hui Xiao Chao, Carson Thoreen, Aaron M. Hosios, Lawrence D. Schweitzer, Yaochung Weng, et al. “Cooperative nutrient accumulation sustains growth of mammalian cells.” Sci Rep 5 (December 1, 2015): 17401. https://doi.org/10.1038/srep17401.
       Full Text  Link to Item
    • Wood, Kris C. “Mapping the Pathways of Resistance to Targeted Therapies.” Cancer Res 75, no. 20 (October 15, 2015): 4247–51. https://doi.org/10.1158/0008-5472.CAN-15-1248.
       Full Text  Link to Item
    • Misale, Sandra, Ivana Bozic, Jingshan Tong, Ashley Peraza-Penton, Alice Lallo, Federica Baldi, Kevin H. Lin, et al. “Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.” Nat Commun 6 (September 22, 2015): 8305. https://doi.org/10.1038/ncomms9305.
       Full Text  Link to Item
    • Gerriets, Valerie A., Rigel J. Kishton, Amanda G. Nichols, Andrew N. Macintyre, Makoto Inoue, Olga Ilkayeva, Peter S. Winter, et al. “Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation.” J Clin Invest 125, no. 1 (January 2015): 194–207. https://doi.org/10.1172/JCI76012.
       Full Text  Open Access Copy  Link to Item
    • Winter, Peter S., Kristopher A. Sarosiek, Kevin H. Lin, Manja Meggendorfer, Susanne Schnittger, Anthony Letai, and Kris C. Wood. “RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.” Sci Signal 7, no. 357 (December 23, 2014): ra122. https://doi.org/10.1126/scisignal.2005301.
       Full Text  Link to Item
    • Martz, Colin A., Kathleen A. Ottina, Katherine R. Singleton, Jeff S. Jasper, Suzanne E. Wardell, Ashley Peraza-Penton, Gray R. Anderson, et al. “Systematic identification of signaling pathways with potential to confer anticancer drug resistance.” Sci Signal 7, no. 357 (December 23, 2014): ra121. https://doi.org/10.1126/scisignal.aaa1877.
       Full Text  Link to Item
    • Wood, K. C., and A. M. VanHook. “Science signaling podcast: 23 December 2014.” Science Signaling 7, no. 357 (December 23, 2014). https://doi.org/10.1126/scisignal.aaa4213.
       Full Text
    • Wood, Kevin B., Kris C. Wood, Satoshi Nishida, and Philippe Cluzel. “Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells.” Cell Rep 6, no. 6 (March 27, 2014): 1073–84. https://doi.org/10.1016/j.celrep.2014.02.007.
       Full Text  Link to Item
    • Wood, Kris C., David J. Konieczkowski, Cory M. Johannessen, Jesse S. Boehm, Pablo Tamayo, Olga B. Botvinnik, Jill P. Mesirov, et al. “MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.” Sci Signal 5, no. 224 (May 15, 2012): rs4. https://doi.org/10.1126/scisignal.2002612.
       Full Text  Link to Item
    • Wood, Kris C., and David M. Sabatini. “Growth signaling at the nexus of stem cell life and death.” Cell Stem Cell 5, no. 3 (September 4, 2009): 232–34. https://doi.org/10.1016/j.stem.2009.08.008.
       Full Text  Link to Item
    • Wood, Kris C., Nicole S. Zacharia, Daniel J. Schmidt, Stefani N. Wrightman, Brian J. Andaya, and Paula T. Hammond. “Electroactive controlled release thin films.” Proceedings of the National Academy of Sciences of the United States of America 105, no. 7 (February 12, 2008): 2280–85. https://doi.org/10.1073/pnas.0706994105.
       Full Text
    • Wood, Kris C., Samira M. Azarin, Wadih Arap, Renata Pasqualini, Robert Langer, and Paula T. Hammond. “Tumor-targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide.” Bioconjug Chem 19, no. 2 (February 2008): 403–5. https://doi.org/10.1021/bc700408r.
       Full Text  Link to Item
    • Wood, K. C., H. F. Chuang, R. D. Batten, D. M. Lynn, and P. T. Hammond. “Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films.” Proceedings of the National Academy of Sciences of the United States of America 103, no. 27 (July 4, 2006): 10207–12. https://doi.org/10.1073/pnas.0602884103.
       Full Text
    • Wood, Kris C., Steven R. Little, Robert Langer, and Paula T. Hammond. “A family of hierarchically self-assembling linear-dendritic hybrid polymers for highly efficient targeted gene delivery.” Angew Chem Int Ed Engl 44, no. 41 (October 21, 2005): 6704–8. https://doi.org/10.1002/anie.200502152.
       Full Text  Link to Item
    • Wood, K. C., J. Q. Boedicker, D. M. Lynn, and P. T. Hammond. “Tunable drug release from hydrolytically degradable layer-by-layer thin films.” Langmuir 21, no. 4 (February 15, 2005): 1603–9. https://doi.org/10.1021/la0476480.
       Full Text
    • Meyer, D. E., K. Wood, L. G. Bachas, and D. Bhattacharyya. “Degradation of chlorinated organics by membrane-immobilized nanosized metals.” Environmental Progress 23, no. 3 (October 1, 2004): 232–42. https://doi.org/10.1002/ep.10031.
       Full Text

  • Conference Papers

    • Garcia, Natalia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, et al. “Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.” In Mol Cancer Ther, 21:170–83, 2022. https://doi.org/10.1158/1535-7163.MCT-21-0194.
       Full Text  Link to Item
    • Paradis, Justine S., Monica Acosta, Nadia Arang, Robert Saddawi-Konefka, Ayush Kishore, Takahito Sugase, Xiaodong Feng, et al. “Abstract 6406: FAK and MEK co-targeting: A new multimodal precision therapy forGNAQ-driven uveal melanoma.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.am2020-6406.
       Full Text
    • Vaseva, Angelina V., Abhik Bandyopadhyay, Vanessa Del Pozo, Craig M. Goodwin, Prson Gautam, Krister Wennerberg, Kris C. Wood, Yidong Chen, Channing J. Der, and Peter J. Houghton. “Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma.” In Cancer Research, 80:72–72, 2020.
       Link to Item
    • Vaseva, Angelina V., Abhik Bandyopadhyay, Vanessa Del Pozzo, Craig M. Goodwin, Prson Gautam, Krister Wennerberg, Kris C. Wood, Channing J. Der, and Peter J. Houghton. “Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma.” In Molecular Cancer Research, 18:59–60, 2020.
       Link to Item
    • Wood, K. C. “Druggable Vulnerabilities in Therapy-Resistant Lung Cancers.” In Journal of Thoracic Oncology, 15:S6–S6. ELSEVIER SCIENCE INC, 2020.
       Link to Item
    • Pardee, Timothy S., Kris C. Wood, Kevin H. Lin, Justine Rutter, Mariaelena Pierobon, Emanuel Petricoin, Susan Lyerly, et al. “Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active.” In Blood, 134:1388–1388. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-129413.
       Full Text
    • Su, Angela, Frank Ling, Camille Vaganay, Bryann Pardieu, Lina Benajiba, Gaetano Sodaro, Justine Pasanisi, et al. “The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.” In Blood, 134:877–877. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-131255.
       Full Text
    • Goodwin, Craig M., Sehrish Javaid, Andrew M. Waters, Bjoern Papke, Runying Yang, Mariaelena Pierobon, Daniel M. Freed, et al. “Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treatKRAS-mutant pancreatic cancer.” In Molecular and Cellular Biology / Genetics. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-lb-287.
       Full Text
    • Wood, Kris C. “Abstract PR18: Leveraging synthetic lethality to target convergent therapeutic resistance.” In Resistance Against Drug Combinations. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-8514.synthleth-pr18.
       Full Text
    • Wood, Kris C. “Leveraging Synthetic Lethality to Target Convergent Therapeutic Resistance.” In Faseb Journal, Vol. 31. FEDERATION AMER SOC EXP BIOL, 2017.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • PHARM 394: Research Independent Study 2022
  • PHARM 494: Research Independent Study 2022
  • PHARM 495: Research Independent Study 2022
  • CMB 710E: Cell & Molecular Biology Module V 2021
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis 2021
  • PHARM 393: Research Independent Study 2021
  • PHARM 394: Research Independent Study 2021
  • PHARM 493: Research Independent Study 2021
  • PHARM 494: Research Independent Study 2021
  • PHARM 495: Research Independent Study 2021
  • PHARM 818: Molecular Mechanisms of Oncogenesis 2021
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I 2021
  • CMB 710E: Cell & Molecular Biology Module V 2020
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis 2020
  • PHARM 393: Research Independent Study 2020
  • PHARM 394: Research Independent Study 2020
  • PHARM 493: Research Independent Study 2020
  • PHARM 494: Research Independent Study 2020
  • PHARM 495: Research Independent Study 2020
  • PHARM 818: Molecular Mechanisms of Oncogenesis 2020
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I 2020

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.